ReviewEuropean respiratory review : an official journal of the European Respiratory Society2014
Pirfenidone: an update on clinical trial data and insights from everyday practice.
Review in European respiratory review : an official journal of the European Respiratory Society, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 38 citations in OpenAlex.
- Therapeutic Potential of Pirfenidone in Adenine-Induced Chronic Kidney Disease: An Integrated Experimental and In Silico Study.Applied biochemistry and biotechnology · 2026Article
- Nanotherapeutic Approaches to Treat COVID-19-Induced Pulmonary Fibrosis.Biotech (Basel (Switzerland)) · 2023Review
- Dual Asymmetric Centrifugation Efficiently Produces a Poloxamer-Based Nanoemulsion Gel for Topical Delivery of Pirfenidone.AAPS PharmSciTech · 2020Article
- Real world experience of response to pirfenidone in patients with idiopathic pulmonary fibrosis: a two centre retrospective study.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2020Observational
- Idiopathic and immune-related pulmonary fibrosis: diagnostic and therapeutic challenges.Clinical & translational immunology · 2019Review
- Cost-effectiveness of pirfenidone compared to all available strategies for the treatment of idiopathic pulmonary fibrosis in France.Journal of market access & health policy · 2019Article
- Review
- Computational Modeling Predicts Simultaneous Targeting of Fibroblasts and Epithelial Cells Is Necessary for Treatment of Pulmonary Fibrosis.Frontiers in pharmacology · 2016Article
- Patient considerations and drug selection in the treatment of idiopathic pulmonary fibrosis.Therapeutics and clinical risk management · 2016Review
- Idiopathic pulmonary fibrosis: from clinical trials to real-life experiences.European respiratory review : an official journal of the European Respiratory Society · 2015Review
- Therapeutic targets for treating fibrotic kidney diseases.Translational research : the journal of laboratory and clinical medicine · 2015Review
- Combined pulmonary fibrosis and emphysema (CPFE): an entity different from emphysema or pulmonary fibrosis alone.Journal of thoracic disease · 2015Review
- Article
- Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives.BioMed research international · 2015Review
- Management of idiopathic pulmonary fibrosis: selected case reports.European respiratory review : an official journal of the European Respiratory Society · 2014Article
- Evolvement of best practice in diagnosis and management of idiopathic pulmonary fibrosis.European respiratory review : an official journal of the European Respiratory Society · 2014Article
Corrections and comments
- Commented on by
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pirfenidone is an orally active, small molecule that inhibits synthesis of profibrotic and inflammatory mediators. It was approved for the treatment of adults with mild-to-moderate idiopathic pulmonary fibrosis in the European Union based on the results of two pivotal phase III, double-blind, randomised, placebo-controlled clinical trials (CAPACITY) demonstrating efficacy and safety, and supported by two Japanese clinical trials (SP2 and SP3). Currently, there is increasing interest in experience with pirfenidone in patients relating to the real-world setting. Following the publication of the CAPACITY clinical studies, additional analyses have been conducted to provide further support for pirfenidone in clinical practice, including a modified per-protocol analysis of the CAPACITY study population. New data from the RECAP extension study also provided longer term data for pirfenidone and promising continuation rates with treatment. Pirfenidone is also being evaluated in specialist centre cohorts providing important information on real-world efficacy and safety. Increasing experience with pirfenidone in everyday clinical practice is helping to establish \expert guidance on the management of known adverse events, together with practical recommendations, to ensure adherence to treatment so that the possible longer term benefits of pirfenidone treatment in reducing lung function decline can be maximised.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.